Can Novartis Reclaim Pioneering Role In Transplantation?
Can Novartis Reclaim Pioneering Role In Transplantation?
$131.00
Novartis is developing a new type of immunosuppressive agent, an anti-CD40 monoclonal antibody, which might allow organ transplants to last longer in recipients, reduce pressure on transplant waiting lists, and improve long-term outcomes. In Vivo interviewed Novartis’ Head of Immunology, Hepatology and Dermatology.
Publisher: InVivo
- Description
Novartis AG has an impressive heritage in the organ transplant sector spanning more than 30 years. Now, they are pioneering a new class of potential products that are in early clinical development. In Vivo spoke to Eric Hughes, Head of Immunology, Hepatology and Dermatology at Novartis about development of a fully human anti-CD40 targeting monoclonal antibody which acts to inhibit the CD40 signaling pathway and inhibit activation of CD40-expressing cells. While many companies are looking at CD40 activation in the development of anticancer agents, only a handful are looking at this immunosuppressive process.
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
MorphoSys: A European Champion Crossing The Biopharma Rubicon 
Sign up to the